Close

AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

AI-Driven Pharmacovigilance with Real-Time Data Monitoring

Pharmacovigilance is about looking out for bad stuff from...

AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.

During this clinical phase, scientists at the Seattle manufacturing site will work to support process optimization, including product qualification, process development, analytical, and regulatory document support to manufacture the product and prepare it for late phase steps.

AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes. The site also recently expanded to add a new microbial-based manufacturing line system.

“Our company has a strong history of antibody production, and we pride ourselves on offering the flexibility and the technical expertise to meet any drug substance need at this critical clinical phase,” said JB Agnus, Chief Business Officer, AGC Biologics. “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories